One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire

Urology

Volumn 55, Issue 4, 2000, Pages 540-546

  Lukacs, B ^a   Grange, J C ^b   Comet, D ^c  

^a HÔPITAL TENON   (France)

^b Laboratoires Synthélabo   (France)

^c Biostatistic Department   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN;

ADULT; AGED; ARTICLE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GENERAL PRACTICE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; QUESTIONNAIRE; SEXUAL FUNCTION; SLOW RELEASE FORMULATION; STATISTICAL ANALYSIS; TREATMENT OUTCOME; URETHRA; URINE RETENTION; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; FAMILY PRACTICE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSTATECTOMY; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; QUINAZOLINES; RECURRENCE; SICKNESS IMPACT PROFILE; URINARY RETENTION; URODYNAMICS;

EID: 0034016247     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00539-7     Document Type: Article

References (28)

1. Boyle P., Maisonneuve P., Steg A. Decrease in mortality from benign prostatic hyperplasia a major unheralded health triumph . J Urol. 55:1996;176-180.
2. Breslin D.S., Muecke E.C., Reckler J.M., et al. Changing trends in the management of prostatic disease in a single private practice a 5-year follow-up . J Urol. 150:1993;346-350.
3. Dowd J.B. Benign prostatic hyperplasia practice makes perfect (editorial) . J Urol. 155:1996;190.
4. Rosier P.F.W.M., de Wildt M.J.A.M., Wijkstra H., et al. Clinical diagnosis of bladder outlet obstruction in patients with benign prostatic enlargement and lower urinary tract symptoms development and urodynamics validation of a clinical prostate score for the objective diagnosis of bladder outlet obstruction . J Urol. 155:1996;1649-1654.
5. Guess H.A., Chute C.G., Garraway W.M., et al. Similar levels of urological symptoms have similar impact on Scottish and American men - although Scots report less symptoms. J Urol. 150:1993;1701-1705.
6. Guyatt G.H., Feeny D.H., Patrick D.L. Measuring health-related quality of life. Ann Intern Med. 118:1993;622-629.
7. Lukacs B., Doubler J.D., Cioffu C., et al. Changes in health related quality of life (HRQL) severity profile as a primary efficacy parameter in 2829 patients treated 1 year with alfuzosin. Eur Urol. 35:(suppl 2):1999;165.
8. McConnell JD, Barry MJ, Bruskewitz RC, et al: Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guideline, No. 8. AHCPR Publication No. 94-0582. Rockville, Md, Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services 225, February 1994.
9. Jardin A., Bensadoun H., Delauche-Cavalier M.C., et al. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet. 337:1991;1457-1461.
10. Buzelin J.M., Roth S., Geffriaud-Ricouard C., et al. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. Eur Urol. 31:1997;190-198.
11. Teillac P., Delauche-Cavallier M.C., Attali P. Urinary flow rates in patients with benign prostatic hyperplasia following treatment with alfuzosin. Br J Urol. 70:1992;58-64.
12. Buzelin J.M., Delauche-Cavallier M.C., Roth S., et al. Clinical uroselectivity evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction . Br J Urol. 79:1997;898-906.
13. Lukacs B., Blondin P., McCarthy C., et al. Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy. Eur Urol. 29:1996;29-35.
14. Sagnier P.P., Richard F., Botto H., et al. Adaptation and cultural validation in French language of the International Prostate Symptom Score (IPSS) and quality of life assessment. Cockett A.T.K., Khoury S., Aso Y., et al. Proceedings of the Second International Consultation on Benign Prostatic Hyperplasia (BPH). 1994;144-147 Scientific Communications International, Channel Islands.
15. Barry M.J., Fowler F.J., O'Leary M.P., et al. The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol. 148:1992;1549-1557.
16. Aso Y., Abbou C., Abrams P., et al. Clinical research criteria. Cockett A.T.K., Khoury S., Aso Y., et al. Proceedings of the Third International Consultation on Benign Prostatic Hyperplasia (BPH). 1996;461-468 Scientific Communications International, Channel Islands.
17. Lukacs B., Comet D., Grange J.C., et al. Construction and validation of a short-form benign prostatic hypertrophy health-related quality of life (HRQL) questionnaire (9 items). Br J Urol. 80:1997;722-730.
18. Mebust W.K., Ackerman R., Barry M.J., et al. Symptoms evaluation, quality of life and sexuality. Cockett A.T.K., Khoury S., Aso Y., et al. Proceedings of the Third International Consultation on Benign Prostatic Hyperplasia (BPH). 1996;257-261 Scientific Communications International, Jersey, Channel Islands.
19. Comparing treatments: safety, effectiveness, and cost-effectiveness. March 23rd/24th Workshop: FDA, Division of Drug Marketing, Advertising and Promotion (DDMAC). Principles for the review of pharmacoeconomic promotion. Script No. 2013, April 4, 1995.
20. Flanagan J.C. Measurement of quality of life current state of the art . Arch Phys Med Rehabil. 63:1982;56-59.
21. Skoog I., Nilsson L., Palmertz B., et al. A population-based study of dementia in 85-year-olds. N Engl J Med. 328:1993;153-158.
22. Jonler M., Moon T., Brannan W., et al. The effect of age, ethnicity and geographical location on impotence and quality of life. Br J Urol. 75:1995;651-655.
23. Girman C.J., Kolman C., Liss C.L., et al. Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia. Prostate. 29:1996;83-90.
24. Lukacs B., Leplège A., Thibault P., et al. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners one year results . Urology. 48:1996;731-740.
25. Roehrborn C.G., Oesterling J.E., Auerbach S., et al. The Hytrin community assessment trial study a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia . Urology. 47:1996;159-168.
26. Lukacs B., Grange J.C., Comet D., et al. 3-year prospective study of 3,228 BPH patients treated with alfuzosin in general practice. Prostate Cancer. 1:1998;276-283.
27. Debruyne F.M.J., Witjes W.P.J., Jardin A., et al. SR-alfuzosin, finasteride, and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol. 34:1998;169-175.
28. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 338:1998;557-563.